A widely used sleeping medication might hold unexpected potential in reducing the buildup of harmful proteins associated with Alzheimer's disease— but here's where it gets controversial... Recent research suggests that common sleep aids could play a surprising role in addressing Alzheimer’s disorder, a condition that still leaves many questions unanswered. The critical connection being explored is how sleep quality impacts the accumulation of toxic protein clusters in the brain, which are central to disease progression.
In a 2023 study, scientists found that taking a popular insomnia medication—suvorexant—over just two nights at a sleep clinic may slightly decrease the levels of amyloid-beta and tau proteins in the cerebrospinal fluid, the fluid responsible for cleansing the brain. These proteins are notorious for congregating into plaques and tangles, respectively, which are hallmarks of Alzheimer’s pathology.
For example, individuals in this study, who were healthy adults without sleep issues or cognitive problems, experienced a modest reduction in these proteins—around 10 to 20 percent—after dosage. Interestingly, higher doses also briefly lowered levels of hyperphosphorylated tau, a form of tau associated with neuronal damage, although this temporary decline was not sustained past a day.
While this study, conducted by researchers at Washington University in St. Louis, is promising and highlights a potential link between sleep enhancement and Alzheimer’s molecular markers, it is essential to view these findings cautiously. The research was brief, involved only a small, healthy cohort, and did not demonstrate changes in sleep architecture—meaning the sleeping patterns remained predominantly the same.
But here’s the catch: Should you start popping sleeping pills to ward off Alzheimer’s? Not so fast. As neurologist Brendan Lucey emphasizes, it’s premature to interpret these results as a clear endorsement for regular use of sleep medications like suvorexant solely for Alzheimer’s prevention. Long-term use of sleeping pills can lead to dependence, and they often promote lighter sleep cycles, which might not be as restorative. Earlier studies have shown that poor sleep quality, especially reduced deep sleep stages, can elevate levels of amyloid-beta and tau proteins, possibly worsening the risk.
In fact, the researchers' goal was to investigate whether improving sleep quality with medication could lower the levels of these proteins in cerebrospinal fluid—a simple but important step, considering prior evidence that even just a single night of disrupted sleep can cause amyloid-beta levels to spike.
In the study, 38 middle-aged volunteers, aged between 45 and 65, were given one of two doses of suvorexant or a placebo after undergoing a spinal tap to extract cerebrospinal fluid. The team then monitored changes in protein levels over the next 36 hours. Remarkably, even without any noticeable differences in sleep duration or quality, protein levels tended to decrease with suvorexant intake.
The findings hint that sleep medications might temporarily influence the proteins linked to Alzheimer’s, suggesting that better sleep could help manage or slow down disease markers—and this is a part most people miss in the broader conversation. However, as Lucey points out, whether these temporary reductions translate into long-lasting benefits requires further study, especially in older populations over longer periods.
Now, it’s important to consider the bigger picture—how do these diseases truly develop? The dominant theory, which has influenced decades of research, posits that amyloid plaques are primary culprits. Yet, recent scrutiny reveals that this might be an oversimplification, especially as numerous drugs targeting amyloid have failed in clinical trials. Some experts are now reconsidering whether amyloid is the root cause or a side effect—pushing us to think more broadly.
So, where does that leave the potential of sleep aids as a preventative strategy? It’s promising but far from conclusive. The link between sleep deprivation, Alzheimer’s, and neurodegeneration is increasingly evident, so improving sleep hygiene—such as addressing sleep disorders like sleep apnea—remains a wise and accessible approach for brain health at any age.
Lucey remains optimistic about future developments, hinting that new medications might someday utilize the sleep-Alzheimer’s link to prevent cognitive decline. But for now, he admits, “We’re not quite there yet.”
This research was published in Annals of Neurology and adds to the ongoing debate about how best to combat Alzheimer’s disease—a condition that continues to challenge scientists and clinicians alike. What do you think? Could targeting sleep patterns be a game-changer? Or is it just another hopeful distraction? Share your thoughts below!
